FGF23, Albuminuria, and Disease Progression in Patients with Chronic IgA Nephropathy
Authors:
- Sigrid LundbergSLSigrid Lundberg
- Abdul Rashid QureshiAQAbdul Rashid Qureshi
- Sara OlivecronaSOSara Olivecrona
- Iva GunnarssonIGIva Gunnarsson
- Stefan H. JacobsonSJStefan H. Jacobson
- Tobias E. LarssonTLTobias E. Larsson
- 1 May 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 7 (5) , 727-734
Abstract
Summary: Background and objectives: Fibroblast growth factor-23 (FGF23) regulates mineral metabolism. Circulatory FGF23 levels are increased and predict outcomes in CKD. However, the relation of FGF23 to albuminuria and disease progression in patients with CKD and one underlying diagnosis is unknown. Design, setting, participants, & measurements: Prospective, observational study in 180 patients with IgA nephropathy (IgAN), CKD stage 1–4, and median 55-month follow-up (range, 12–177 months). Primary outcomes were (1) time-averaged albuminuria, (2A) progression to CKD stage 5 or ≥50% loss of estimated GFR, (2B) progression to CKD stage 5 or ≥25% loss of estimated GFR within 10 years, and (3) annual loss of estimated GFR. Results: FGF23 was independently associated with baseline and time-averaged albuminuria (change in 1 g/24 hour albuminuria per increase in log FGF23: β = 0.26; P=0.02). Log FGF23 predicted CKD progression in crude models and after adjustment for mineral metabolites (endpoints 2A and 2B). It remained significant after adjustments for age, sex, serum albumin, calcium, phosphate, parathyroid hormone, 25-hydroxyvitamin D, baseline albuminuria, baseline estimated GFR, mean arterial BP, body mass index, and angiotensin-converting enzyme inhibitors/angiotensin-receptor blocker use in endpoint 2B (hazard ratio, 2.53; P=0.02) but not endpoint 2A (hazard ratio, 2.01; P=0.43). Log FGF23 predicted annual loss of estimated GFR in the same model (change in ml/min per 1.73 m2 per increase in log FGF23, 1.50; P=0.008). Conclusions: In patients with CKD and IgAN, FGF23 was associated with albuminuria and CKD progression, a finding that suggests its role as a potential biomarker in IgAN.Keywords
This publication has 45 references indexed in Scilit:
- Klotho Deficiency Causes Vascular Calcification in Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2011
- FGF23 or PTH: which comes first in CKD ?Kidney International, 2010
- Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trialThe Lancet, 2010
- Fibroblast Growth Factor 23 and Fetuin A are Independent Predictors for the Coronary Artery Disease Extent in Mild Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2010
- PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loopAmerican Journal of Physiology-Renal Physiology, 2010
- FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney diseaseKidney International, 2010
- The Associations of Fibroblast Growth Factor 23 and Uncarboxylated Matrix Gla Protein With Mortality in Coronary Artery Disease: The Heart and Soul StudyAnnals of Internal Medicine, 2010
- Regulation of C-Terminal and Intact FGF-23 by Dietary Phosphate in Men and WomenJournal of Bone and Mineral Research, 2006
- Dietary and Serum Phosphorus Regulate Fibroblast Growth Factor 23 Expression and 1,25-Dihydroxyvitamin D Metabolism in MiceEndocrinology, 2005
- Fibroblast Growth Factor-23 Is Regulated by 1α,25-Dihydroxyvitamin DJournal of Bone and Mineral Research, 2005